In a column for NeurologyLive, multiple sclerosis researcher discussed the primary challenges of demonstrating biological drug effects during short-duration trials.
Measurement remains one of the central hurdles in assessing remyelination treatments.
Researchers currently deploy tests of nerve function, such as visual evoked potential latency. As myelin repairs, that latency shortens. Alternatively, teams apply myelin-sensitive MRI sequences to examine nerve structure.
These approaches have seen varying success over the past ten years.
Translating those structural and functional findings into clinically meaningful impacts for trial participants remains difficult.
“What we’re trying to do at the moment is demonstrate that our drugs are having a biological effect over short-duration trials,” the expert wrote in the column.
Visual outcome measures prove highly sensitive for detecting remyelination during short trials. Changes in full-field visual evoked potential latency lead current methods because they show statistically significant effects across clinical trials.
Participant selection represents another critical design factor. Remyelinating treatments require abundant nerve fibers that are ready to be repaired. In advanced multiple sclerosis, more nerve fibers degenerate after prolonged myelin loss.
Effects are greatest and easiest to measure in patients early in their disease journey. Trials should test this initial cohort to secure a go or no-go signal before expanding to patients with advanced needs.
“The key thing we’ve learned is that visual outcome measures are highly sensitive to detecting a remyelinating effect over a short-duration trial,” the author said.
Trial duration must account for axonal protection, which emerges over years rather than months. Researchers must capture long-term data three to five years after short trials or conduct longer studies.
Current trials rely on repurposed medications designed for other reasons to stimulate oligodendrocyte precursor cells. Future research will introduce novel drugs targeted specifically at this process.
Novel blood biomarkers and improved myelin imaging will help stratify lesions according to repair potential. These advances aim to prove the long-term benefits of remyelinating drugs in multiple sclerosis care.
“It’s an exciting time to be part of myelin repair research, and the next 5 to 10 years will be really exciting,” the researcher concluded.